Divalproex Sodium Tablet, Delayed Release
Product Images NDC 55154-7145

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 55154-7145). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bag Label (Bf6c7836 051e 4281 97c6 483901208c6f 00)

This is a package of Divalproex Sodium Delayed-Release Tablets with NDC code 55154-4679-0. Each tablet contains 500mg of valproic acid. The package contains 10 tablets, and the usual dosage is described in the product insert. The package should be stored between 20-25°C. The package is not child-resistant and is intended for institutional use only. The drug product is from NDC # 57237-048, produced by Rising Health LLC., and packaged and distributed by American Health Packaging, a subsidiary of AmerisourceBergen Company. The package is distributed by Cardinal Health. A medication guide is included.*

FDA Label Image

Bag Label (Bf6c7836 051e 4281 97c6 483901208c6f 01)

This is a description of a medication called Divalproex Sodium delayed-release tablets. This pack has 10 tablets of 250mg each containing divalproex sodium USP equivalent to valproic acid 230g in enteric-coated delayed-release form. The drug is for Outpatient Use Only and must be kept out of reach of children. The package must not be used if already opened or has any sign of damage. The drug is dispensed with a medication guide for each patient. Storage instructions are provided on the package. The package is not intended for institutional use. The name of the manufacturer and distributor is also given. There are no non-English characters in the text.*

FDA Label Image

Figure 1 (Divalproex Fig1)

FDA Label Image

Figure 2 (Divalproex Fig2)

FDA Label Image

Figure 3 (Divalproex Fig3)

FDA Label Image

Figure 4 (Divalproex Fig4)

The text describes the mean 4-week migraine rates for two studies comparing the placebo to Divalproex Sodium delayed-release tablets. Study 1 used a mean dose of 1,087 mg/day while study 2 used a dose of either 500 or 1,000 mg/day.*

FDA Label Image

Chemical Structure (Divalproex Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.